Development and Characterization of Biphenylsulfonamides as Novel Inhibitors of Bone Resorption

Iain Robert Greig, A. I. Idris, S. H. Ralston, R. J. van't Hof

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Increased osteoclastic bone resorption plays a central role in the pathogenesis of many bone diseases, and osteoclast inhibitors are the most widely used treatments for these diseases. We have identified and characterized a series of novel biphenylsulfonamide derivatives that have potent inhibitory effects on osteoclastic bone resorption in vitro and that prevent ovariectomy-induced bone loss in vivo. A number of aromatic substituted derivatives were prepared and a QSAR model was generated, which allowed accurate prediction of compound potency. Using this model, we have prepared compounds able to inhibit osteoclast formation and bone resorption in vitro at concentrations in the nanomolar range. One such compound, 55 (ABD295) (Greig, I. R.; Mohamed, A. I.; Ralston, S. H.; van't Hof, R. J. Alkyl Aryl Sulfonamides as Therapeutic Agents for the Treatment of Bone Conditions. GB Patent WO2005118528, 2005), fully reversed ovariectomy-induced bone loss in mice at a dose of 5 (mg/kg)/day. In conclusion, biphenylsulfonamides like 55 form a new class of potent antiresorptive agents with possible therapeutic use in diseases characterized by increased bone resorption.

Original languageEnglish
Pages (from-to)7487-7492
Number of pages6
JournalJournal of Medicinal Chemistry
Volume49
Issue number25
DOIs
Publication statusPublished - Nov 2006

Keywords

  • hormone-replacement therapy
  • million women
  • bisphosphonates
  • alendronate
  • osteoperosis
  • selection
  • disease
  • cancer
  • risk

Cite this

Development and Characterization of Biphenylsulfonamides as Novel Inhibitors of Bone Resorption. / Greig, Iain Robert; Idris, A. I.; Ralston, S. H.; van't Hof, R. J.

In: Journal of Medicinal Chemistry, Vol. 49, No. 25, 11.2006, p. 7487-7492.

Research output: Contribution to journalArticle

Greig, Iain Robert ; Idris, A. I. ; Ralston, S. H. ; van't Hof, R. J. / Development and Characterization of Biphenylsulfonamides as Novel Inhibitors of Bone Resorption. In: Journal of Medicinal Chemistry. 2006 ; Vol. 49, No. 25. pp. 7487-7492.
@article{2f8496b98a8247bfa5d023f822dbc03e,
title = "Development and Characterization of Biphenylsulfonamides as Novel Inhibitors of Bone Resorption",
abstract = "Increased osteoclastic bone resorption plays a central role in the pathogenesis of many bone diseases, and osteoclast inhibitors are the most widely used treatments for these diseases. We have identified and characterized a series of novel biphenylsulfonamide derivatives that have potent inhibitory effects on osteoclastic bone resorption in vitro and that prevent ovariectomy-induced bone loss in vivo. A number of aromatic substituted derivatives were prepared and a QSAR model was generated, which allowed accurate prediction of compound potency. Using this model, we have prepared compounds able to inhibit osteoclast formation and bone resorption in vitro at concentrations in the nanomolar range. One such compound, 55 (ABD295) (Greig, I. R.; Mohamed, A. I.; Ralston, S. H.; van't Hof, R. J. Alkyl Aryl Sulfonamides as Therapeutic Agents for the Treatment of Bone Conditions. GB Patent WO2005118528, 2005), fully reversed ovariectomy-induced bone loss in mice at a dose of 5 (mg/kg)/day. In conclusion, biphenylsulfonamides like 55 form a new class of potent antiresorptive agents with possible therapeutic use in diseases characterized by increased bone resorption.",
keywords = "hormone-replacement therapy, million women, bisphosphonates, alendronate, osteoperosis, selection, disease, cancer, risk",
author = "Greig, {Iain Robert} and Idris, {A. I.} and Ralston, {S. H.} and {van't Hof}, {R. J.}",
year = "2006",
month = "11",
doi = "10.1021/JM051236M",
language = "English",
volume = "49",
pages = "7487--7492",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "AMER CHEMICAL SOC",
number = "25",

}

TY - JOUR

T1 - Development and Characterization of Biphenylsulfonamides as Novel Inhibitors of Bone Resorption

AU - Greig, Iain Robert

AU - Idris, A. I.

AU - Ralston, S. H.

AU - van't Hof, R. J.

PY - 2006/11

Y1 - 2006/11

N2 - Increased osteoclastic bone resorption plays a central role in the pathogenesis of many bone diseases, and osteoclast inhibitors are the most widely used treatments for these diseases. We have identified and characterized a series of novel biphenylsulfonamide derivatives that have potent inhibitory effects on osteoclastic bone resorption in vitro and that prevent ovariectomy-induced bone loss in vivo. A number of aromatic substituted derivatives were prepared and a QSAR model was generated, which allowed accurate prediction of compound potency. Using this model, we have prepared compounds able to inhibit osteoclast formation and bone resorption in vitro at concentrations in the nanomolar range. One such compound, 55 (ABD295) (Greig, I. R.; Mohamed, A. I.; Ralston, S. H.; van't Hof, R. J. Alkyl Aryl Sulfonamides as Therapeutic Agents for the Treatment of Bone Conditions. GB Patent WO2005118528, 2005), fully reversed ovariectomy-induced bone loss in mice at a dose of 5 (mg/kg)/day. In conclusion, biphenylsulfonamides like 55 form a new class of potent antiresorptive agents with possible therapeutic use in diseases characterized by increased bone resorption.

AB - Increased osteoclastic bone resorption plays a central role in the pathogenesis of many bone diseases, and osteoclast inhibitors are the most widely used treatments for these diseases. We have identified and characterized a series of novel biphenylsulfonamide derivatives that have potent inhibitory effects on osteoclastic bone resorption in vitro and that prevent ovariectomy-induced bone loss in vivo. A number of aromatic substituted derivatives were prepared and a QSAR model was generated, which allowed accurate prediction of compound potency. Using this model, we have prepared compounds able to inhibit osteoclast formation and bone resorption in vitro at concentrations in the nanomolar range. One such compound, 55 (ABD295) (Greig, I. R.; Mohamed, A. I.; Ralston, S. H.; van't Hof, R. J. Alkyl Aryl Sulfonamides as Therapeutic Agents for the Treatment of Bone Conditions. GB Patent WO2005118528, 2005), fully reversed ovariectomy-induced bone loss in mice at a dose of 5 (mg/kg)/day. In conclusion, biphenylsulfonamides like 55 form a new class of potent antiresorptive agents with possible therapeutic use in diseases characterized by increased bone resorption.

KW - hormone-replacement therapy

KW - million women

KW - bisphosphonates

KW - alendronate

KW - osteoperosis

KW - selection

KW - disease

KW - cancer

KW - risk

U2 - 10.1021/JM051236M

DO - 10.1021/JM051236M

M3 - Article

VL - 49

SP - 7487

EP - 7492

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 25

ER -